Loading...
Loading...
Forest Laboratories, Inc.
FRX and Pierre Fabre Laboratories
announced today that FETZIMA (levomilnacipran extended-release
capsules), a once-daily serotonin and norepinephrine reuptake inhibitor
(SNRI), discovered by Pierre Fabre Laboratories and co-developed by
Forest Laboratories, Inc. was approved by the U.S. Food and Drug
Administration (FDA) for the treatment of Major Depressive Disorder
(MDD) in adults.
Major Depressive Disorder, also known as depression, is a common
debilitating disorder in which feelings of sadness and other symptoms
interfere with a person's ability to work, sleep, study, eat, and enjoy
once-pleasurable activities. MDD affects almost 16 million adults in the
United States every year, with a range of severity from mild to severe.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in